IL254277B - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
IL254277B
IL254277B IL254277A IL25427717A IL254277B IL 254277 B IL254277 B IL 254277B IL 254277 A IL254277 A IL 254277A IL 25427717 A IL25427717 A IL 25427717A IL 254277 B IL254277 B IL 254277B
Authority
IL
Israel
Prior art keywords
inhibitors
activity
bicyclic heteroaryl
fused bicyclic
prolyl hydroxylase
Prior art date
Application number
IL254277A
Other languages
English (en)
Hebrew (he)
Other versions
IL254277A0 (en
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL254277A0 publication Critical patent/IL254277A0/en
Publication of IL254277B publication Critical patent/IL254277B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL254277A 2015-03-18 2017-09-03 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors IL254277B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (2)

Publication Number Publication Date
IL254277A0 IL254277A0 (en) 2017-10-31
IL254277B true IL254277B (en) 2020-10-29

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254277A IL254277B (en) 2015-03-18 2017-09-03 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712153B1 (en) 2016-02-24 2021-12-01 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN117304171A (zh) * 2020-04-20 2023-12-29 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
EP4232444A4 (en) * 2020-10-20 2024-09-11 Amgen Inc. HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
WO2023111990A1 (en) * 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
PL360027A1 (en) 2000-06-30 2004-09-06 Wyeth Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
SG178049A1 (en) * 2009-07-17 2012-03-29 Japan Tobacco Inc Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
HK1249512A1 (en) 2018-11-02
CR20170468A (es) 2018-04-27
SG11201707280VA (en) 2017-10-30
JP2018512408A (ja) 2018-05-17
BR112017019653B1 (pt) 2023-10-03
GB201504565D0 (en) 2015-05-06
PH12017501699B1 (en) 2023-06-30
US20180072714A1 (en) 2018-03-15
WO2016148306A1 (en) 2016-09-22
AU2016234209A1 (en) 2017-10-12
JP6726681B2 (ja) 2020-07-22
TN2017000384A1 (en) 2019-01-16
CL2017002354A1 (es) 2018-05-04
CA2979024C (en) 2024-02-20
GEAP201914608A (en) 2019-10-10
CN107531698A (zh) 2018-01-02
UA123668C2 (uk) 2021-05-12
ECSP17069696A (es) 2018-02-28
EA035739B1 (ru) 2020-08-03
CO2017009353A2 (es) 2017-11-30
ZA201706612B (en) 2019-01-30
MY194873A (en) 2022-12-21
KR102609431B1 (ko) 2023-12-04
KR20170129874A (ko) 2017-11-27
EA201792057A1 (ru) 2018-04-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
IL254277A0 (en) 2017-10-31
EP3271357B1 (en) 2019-11-27
DOP2017000209A (es) 2017-10-15
PT3271357T (pt) 2020-02-21
BR112017019653A2 (pt) 2018-05-15
DK3271357T3 (da) 2020-02-17
ES2774052T3 (es) 2020-07-16
MX2017011902A (es) 2017-12-15
CA2979024A1 (en) 2016-09-22
AU2016234209B2 (en) 2020-08-27
NZ735631A (en) 2023-07-28
HUE047918T2 (hu) 2020-05-28
GEP20207095B (en) 2020-04-10
US10287286B2 (en) 2019-05-14
CN107531698B (zh) 2024-08-13
PH12017501699A1 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
IL254277B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
CY2022004I2 (el) Συγχωνευμενες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
CL2016002524A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores irak4
HUE057838T2 (hu) SHP2 inhibitorokként hasznos új heterociklusos származékok
EP3468953C0 (en) SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS
HRP20181650T1 (hr) Biciklički heterociklički derivati kao inhibitori bromodomene
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
PT3209656T (pt) Compostos de indol carboxamida úteis como inibidores de quinase
DK3233863T3 (da) Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
HUE041926T2 (hu) IRAK4 inhibitor biciklusos heterociklilszármazékok
EP3386590A4 (en) BICYCLIC INHIBITORS OF PAD4
ME03485B (me) Derivati benzimidazola kao inhibitori bromodomena
HUE063541T2 (hu) Eljárások piruvát-kináz aktivátorok alkalmazására
EP3684772C0 (en) CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
PT3457851T (pt) Derivados de sobetiroma
EP3556758C0 (en) 1,2-DIHYDRO-1,6-NAPHTHYRIDIN-2-ONE DERIVATIVES AS CDK4/6 INHIBITORS
IL250613B (en) Substituted bicyclic compounds
FR3023290B1 (fr) Derives de flavaglines
LT3347356T (lt) Tricikliniai sulieti piridin-2-ono dariniai ir jų naudojimas kaip brd4 inhibitorių
PL3200786T3 (pl) Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS
EP3661935A4 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES THAT MAY BE USED AS KINASE INHIBITORS
EP3526216C0 (en) BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed